Prepared for
Digital Health
Hero Finding
A vast majority of health system executives rate the performance improvement platform moderately to very valuable, and a majority would recommend serious evaluation: the concept clears the market threshold, but role-based enthusiasm bifurcates.
Across 151 C-Suite and VP leaders at acute care health systems, a vast majority rate the concept moderately to very valuable. CQOs and COOs are the strongest advocates (a majority of each rate it very or extremely valuable), driven by the promise of proactive, real-time monitoring. CMOs show high very-valuable ratings but the lowest extremely-valuable score, reflecting measured optimism contingent on physician trust in automated analytics. CFOs are the most cautious: a majority rate the concept only moderately valuable, with AI accuracy and financial justification as primary concerns.
Vast majority
Rate the platform moderately to very valuable
Majority
Would recommend serious evaluation
Top component
Automated root cause rated transformative or high incremental value
Mid-six-figure
Optimal annual price band
Study Design
N=151 C-Suite and VP leaders at acute care health systems above a mid-revenue threshold · structured quantitative survey with concept exposure.
The sample was designed to reach the executives with budget authority and organizational influence over enterprise performance improvement technology purchases, balanced across organization type, revenue tier, region, and the four functional roles closest to the use case.
Sample segmentation
Large IDN · 62
Academic Medical Center · 55
Independent System · 34
Interview guide · core topics
- Performance monitoring, issue routing, and root cause workflows: tools, owners, and resolution timelines
- Concept reaction: initial value rating, recommendation to evaluate, and concerns by C-Suite role
- Component-level incremental value: signal detection, automated root cause, ownership routing, best practice library
- MVP classification: which capabilities are essential for launch versus future enhancement
- Buying group composition: initiators, evaluators, approvers, and final decision authority
- Evaluation-to-go-live timeline, budget ownership, and funding sources
- Trust and adoption requirements for automated root cause analysis: validation, transparency, governance
- Pricing thresholds and preferred licensing models: fixed annual, outcomes-linked, hybrid, tiered, per-use-case
Recruit criteria
- C-Suite executive (Chief level) or Senior VP, EVP, or VP at an acute care hospital or health system
- Functional role in Quality, Operations, Medical Affairs, or Finance with influence over performance improvement technology decisions
- Organization above a mid-revenue threshold in net patient revenue; majority materially above
- Decision-maker or significant influencer on enterprise technology selection, budget approval, or buying group participation
Key Findings
What the research surfaced for product strategy and commercial planning.
Six signals defined the MVP feature set, the buying group blueprint, and the commercial model parameters.
Vast majority
Rate the platform moderately to very valuable
Top component
Automated root cause rated transformative or high value
Majority
Report resolution cycles of 2 weeks to 2 months
Majority
Would fund through enterprise tech or transformation budgets
Top model
Fixed annual licensing leads as the preferred pricing model
Mid-six-figure
Optimal annual price band
01
Current performance improvement workflows are predominantly manual, fragmented, and slow: a majority report resolution cycles of two weeks to two months.
Root cause analysis depends on labor-intensive chart reviews, emails, and committee meetings. A meaningful share cite manual investigation as the primary approach. A similar share rely on EHR-centric data foundations that require manual analytics. Tracking happens on spreadsheets and emails. Executives identify acceleration and proactive detection, automation, and integration of fragmented data sources as the top desired changes.
02
Concept enthusiasm bifurcates by C-Suite role: CQOs and COOs lead, CMOs are conditionally optimistic, CFOs require financial proof.
CQOs and COOs are the strongest advocates (a majority of each rate it very or extremely valuable), driven by proactive, real-time monitoring. CMOs rate high on very valuable but lowest on extremely valuable, with adoption contingent on physician trust in automated analytics. CFOs show the highest moderately valuable rating and cite AI accuracy and reliability and financial justification as primary concerns. Implementation feasibility, not conceptual objection, drives the gap.
03
Automated root cause is the highest-value MVP component and the most divided trust response.
Automated root cause leads all components in incremental value rating, ahead of monitoring and signal detection and prioritization. Reactions split: a meaningful share express immediate enthusiasm for operational efficiency gains, a smaller minority voice skepticism about accuracy and reliability, and another minority express conditional enthusiasm requiring empirical validation. Published evidence and case studies are the single most critical trust requirement, followed by data source transparency and validation by clinical experts.
04
Length of stay, readmissions, and infection prevention are the top use cases; financial sustainability drives operational metric prioritization.
LOS reduction, readmission reduction, and infection and complication prevention are the most common use cases. When forced to rank, LOS, infection and complication prevention, and mortality improvement emerge as the highest priorities. LOS reduction is rationalized by financial sustainability under fixed payment and cost pressure, while infection prevention and mortality improvement are driven by clinical mission. LOS dominates daily executive attention as the most universally cited priority.
05
The buying group is collaborative and multi-layered: clinical and quality leadership initiate, CFOs control budgets, enterprise budgets fund.
Clinical and quality leadership initiates a meaningful share of evaluations. Final purchasing authority is distributed: a meaningful share use collaborative multi-executive decision-making, others centralize to a single C-Suite executive, and a smaller share use formal committee or board governance. CFOs control budgets in roughly half of organizations. A majority would fund the platform through enterprise-level technology or transformation budgets. The evaluation-to-go-live timeline is 6 to 18 months for a strong majority of organizations.
06
Optimal price lands within a well-defined band with role-based variation; fixed annual licensing leads, with CFOs the lone outlier on outcomes-linked pricing.
The optimal annual price band sits in the mid-six-figure range with an acceptable range running from low- to upper-six figures. CQOs and CMOs anchor higher within the band and tolerate the highest ceilings; COOs are most price-sensitive within the band; CFOs show the lowest optimal but the highest upper ceiling. Fixed annual licensing is the dominant overall preference, driven by budget predictability. Outcomes-linked pricing is the secondary preference, driven by shared risk and accountability; CFOs are the only role where outcomes-linked approaches plurality support. Hybrid models attract the most sophisticated buyers.
“Actually, it's quite exciting. Not to have to wait until the end of the week or the end of the month to understand that there is variance happening. It's a proactive versus reactive system.”— Chief Operating Officer, Academic Medical Center
Crosstab · Concept Value by Role
CQOs and COOs lead concept enthusiasm; CFOs concentrate at moderately valuable: a wide gap on extremely valuable between COOs and CMOs defines the role-based positioning challenge.
Concept value distribution across the four C-Suite roles closest to the platform use case (indexed within row to peak = 100). The bifurcation between operational and clinical-financial roles defines the role-targeted messaging and proof requirements.
| Extremely valuable | Very valuable | Moderately valuable | |
|---|---|---|---|
| Chief Quality Officer (n=52) | 51 | 100 | 84 |
| Chief Operating Officer (n=44) | 100 | 78 | 84 |
| Chief Medical Officer (n=33) | 6 | 100 | 69 |
| Chief Financial Officer (n=22) | 15 | 39 | 100 |
N=151 C-Suite and VP leadersCOO extremely valuable leads materially over CMOCFO moderately valuable leads materially over COOIndexed · blinded values
Heat Map · Component Incremental Value
Automated root cause and proactive monitoring lead component value across every C-Suite role.
Component rating intensity by role (indexed within row to peak = 100); each cell shows how that role rates the component as transformative or high incremental value, relative to the strongest cell in the row.
| CQO | COO | CMO | CFO | |
|---|---|---|---|---|
| Automated root cause surfacing | 100 | 96 | 88 | 78 |
| Proactive real-time monitoring | 100 | 93 | 87 | 73 |
| Signal detection and prioritization | 100 | 97 | 89 | 79 |
| Ownership and action routing | 95 | 100 | 85 | 69 |
| Best practice library | 100 | 95 | 91 | 73 |
Voice of Customer
How health system executives describe the workflow gap and the concept fit.
Verbatims from interviews across the sample, selected to represent the range of views on workflow pain, component value, trust requirements, and pricing model preference.
Workflow Pain · Manual Process
“So the root cause analysis, you know, this is typically a manual process for us. We don't really have a platform or a way to automate, I guess, you could say. So it's a manual dive. It does take us about, I'd say, a minimum two to four weeks depending on the severity of the issue.”
— Chief Operating Officer, Academic Medical Center
Concept Fit · Initial Reaction
“If I could change one thing, it would be to create a real-time digital intelligent dashboard. It feels like our thirty to sixty day lag creates a performance problem and time gaps between when we have the information and have something to do about it.”
— Chief Medical Officer, Academic Medical Center
Component Value · Automated RCA
“The root cause analysis seems to be highly powerful, especially if it is a signal driven by statistically correlated drivers. This will eliminate the opinions and personalities that are currently in place with a very manual discussion-based system.”
— Chief Medical Officer, Academic Medical Center
Trust Requirement · Validation
“I think Automated Root Cause Surfacing, if it actually had strong correlation where it was believable and they had some scores around 90% trustworthiness around the root cause surfacing, I would put this as a five. Until that actually comes to fruition, I just have a hard time believing this is actually the case.”
— Chief Operating Officer, Large Integrated Delivery Network
Pricing Model · Fixed Annual
“For my organization, a fixed annual fee will be clearly much better because our health care system is operating in a non-fixed budget. I have to do annual budget, but as approved by the board. So it's better for me to have predictability for cost of such system.”
— Chief Operating Officer, Academic Medical Center
Counter-intuitive
CFOs anchor lowest on optimal price but tolerate the highest ceiling, and they are the only role where outcomes-linked pricing approaches plurality support.
The prevailing assumption is that CFOs are the toughest pricing constraint. The data tells a more textured story. CFOs do anchor the lowest optimal price within the band and rate the concept most cautiously. But they also tolerate the highest upper ceiling when the financial case is demonstrated, and they are the only role where outcomes-linked pricing approaches plurality support. The implication for commercial design is that the CFO conversation is not about discounting to a fixed-fee floor; it is about offering an outcomes-linked or hybrid model that lets the CFO underwrite a higher contract value against demonstrated savings.
Strategic Implications
Three product and commercial moves from the research.
What the platform sponsor took into MVP scoping, buying group enablement, and commercial model design, grounded in the concept value, component, and pricing data.
01
Scope MVP around automated root cause and proactive monitoring; treat best-practice library and ownership routing as fast-followers.
Automated root cause and proactive monitoring are the two components that command MVP-essential classification across every role. Signal detection and prioritization belongs in the launch envelope. Ownership routing and best-practice library should ship as Phase 2 capabilities tied to expansion accounts, not as launch-blocking scope.
02
Build role-targeted proof: published evidence for CMOs, automated RCA validation for COOs, and financial case-study libraries for CFOs.
Concept enthusiasm bifurcates by role and the proof requirements bifurcate with it. CQO and COO accounts will move on operational efficiency demonstrations. CMO accounts require physician-trust assets: published evidence as the top trust requirement, validation by clinical experts, and methodological transparency. CFO accounts require financial justification packages: ROI models, FTE-hour savings, and outcomes-linked pricing options.
03
Lead commercial offer with fixed annual licensing within the optimal band, with a hybrid outcomes-linked option for CFO-led deals.
Fixed annual licensing is the dominant preference, driven by budget predictability. Anchor the offer within the mid-six-figure optimal band, with an acceptable range running from low- to upper-six figures. Layer a hybrid outcomes-linked variant for accounts where the CFO is the gating decision-maker; CFOs are the only role where outcomes-linked pricing reaches plurality support. Position enterprise technology and transformation budgets as the procurement path, not departmental quality budgets.
Success criteria · 12 months
- MVP ships with automated root cause, proactive monitoring, and signal detection as launch-essential capabilities
- Role-specific proof libraries built for CMO (clinical validation) and CFO (financial case) before first wave of enterprise demos
- Fixed annual list price set within the mid-six-figure optimal band; outcomes-linked variant available for CFO-led deals
- Reference accounts secured across Large IDN, Academic Medical Center, and Independent System segments
Risk register
| Physician trust gating CMO adoption | HIGH |
| AI accuracy concerns from CFO segment | HIGH |
| 6 to 18 month evaluation-to-go-live cycles | MED |
| Budget predictability vs. outcomes-linked tension | MED |
| Smaller organization affordability gap | LOW |